Genmab enters antibody commercialization agreement with Oxford Biotherapeutics — MedWatch
Project Profile: Genmab | Lab Manager
OREGA enters into a License Agreement with Genmab - Orega Biotech
Genmab Signs an Agreement with Tempus to Develop Novel Targets and Biomarkers for Cancer Indications
Jeremy Bastid, auteur sur Orega Biotech - Page 2 of 6
Genmab A/S (GMAB) Stock Price, Quote & News - Stock Analysis
GENMAB ANNOUNCES ASSET EXCHANGE AGREEMENT
Jean-Philippe Vert on LinkedIn: Owkin signs research agreement with Genmab A/S to explore the biological…
Genmab Showcases Program Data in B-Cell Lymphoma Patients
Genmab - ADR Aktie News
All News
GENMAB ANNOUNCES STRATEGY UPDATE PRESENTATION
GENMAB TO PRESENT AT TWO INVESTOR CONFERENCES IN SEPTEMBER
GENMAB COMPLETES ACCRUAL IN HUMAX-CD20 PHASE II RA STUDY
Genmab's Epcoritamab (DuoBody-CD3xCD20) Receives the US FDA's Orphan-Drug Designation for the Treatment of Follicular Lymphoma
Buy Genmab stock (GMAB) | Lightyear
GENMAB'S STRATEGY UPDATE
REGISTRATION OF CAPITAL INCREASE
1/2 Release no. 41/2002 Contact: GENMAB APPLIES TO DELIST FROM THE NEUER MARKT AND THE FRANKFURT STOCK EXCHANGE Resume: Genmab t
Genmab and Johnson & Johnson disappoint with lung cancer drug data — MedWatch
Genmab partner receives conditional EU approval for cancer drug — MedWatch
Genmab silent on new investor role in private equity fund — MedWatch
Genmab et ADC Therapeutics annoncent un accord amendé pour le camidanlumab tésirine (Cami) | Business Wire
News and Media | Genmab
Genmab buys ADC technology license from Synaffix — MedWatch
Ian Wilson on LinkedIn: Team ImaginAb looking forward to supplying CD8 ImmunoPET the GenMab. I…
